Fibrocell Science, Inc.
If you purchased Fibrocell Science, Inc. securities and would like to join the action, please click "Join This Action" below.
FIBROCELL SCIENCE MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF FIBROCELL SCIENCE, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – FCSC
September 13, 2019.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Fibrocell Science, Inc. (NASDAQ: FCSC) to Castle Creek Pharmaceutical Holdings, Inc. (“Castle Creek”) for $3.00 per share is fair to Fibrocell Science shareholders. On behalf of Fibrocell Science shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
The Fibrocell Science merger investigation concerns whether Fibrocell Science and its Board of Directors violated the federal securities laws and/or their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for Fibrocell Science shareholders; (2) determine whether Castle Creek is underpaying for Fibrocell Science; and (3) disclose all material information necessary for Fibrocell Science shareholders to adequately assess and value the merger consideration.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.